139 related articles for article (PubMed ID: 33438526)
1. Oncogenic potential of ATAD2 in stomach cancer and insights into the protein-protein interactions at its AAA + ATPase domain and bromodomain.
Nayak A; Kumar S; Singh SP; Bhattacharyya A; Dixit A; Roychowdhury A
J Biomol Struct Dyn; 2022 Aug; 40(12):5606-5622. PubMed ID: 33438526
[TBL] [Abstract][Full Text] [Related]
2. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.
Gay JC; Eckenroth BE; Evans CM; Langini C; Carlson S; Lloyd JT; Caflisch A; Glass KC
Proteins; 2019 Feb; 87(2):157-167. PubMed ID: 30520161
[TBL] [Abstract][Full Text] [Related]
3. HIF1α-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia.
Nayak A; Roy AD; Rout N; Singh SP; Bhattacharyya A; Roychowdhury A
Biochem Biophys Res Commun; 2020 Mar; 523(4):916-923. PubMed ID: 31959473
[TBL] [Abstract][Full Text] [Related]
4. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain.
Evans CM; Phillips M; Malone KL; Tonelli M; Cornilescu G; Cornilescu C; Holton SJ; Gorjánácz M; Wang L; Carlson S; Gay JC; Nix JC; Demeler B; Markley JL; Glass KC
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502039
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.
Miller DC; Martin MP; Adhikari S; Brennan A; Endicott JA; Golding BT; Hardcastle IR; Heptinstall A; Hobson S; Jennings C; Molyneux L; Ng Y; Wedge SR; Noble MEM; Cano C
Org Biomol Chem; 2018 Mar; 16(11):1843-1850. PubMed ID: 29469144
[TBL] [Abstract][Full Text] [Related]
6. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
7. The ATAD2 bromodomain binds different acetylation marks on the histone H4 in similar fuzzy complexes.
Langini C; Caflisch A; Vitalis A
J Biol Chem; 2017 Oct; 292(40):16734-16745. PubMed ID: 28798233
[TBL] [Abstract][Full Text] [Related]
8. Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains.
Phillips M; Malone KL; Boyle BW; Montgomery C; Kressy IA; Joseph FM; Bright KM; Boyson SP; Chang S; Nix JC; Young NL; Jeffers V; Frietze S; Glass KC
J Med Chem; 2024 May; 67(10):8186-8200. PubMed ID: 38733345
[TBL] [Abstract][Full Text] [Related]
9. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.
Fu J; Zhang J; Chen X; Liu Z; Yang X; He Z; Hao Y; Liu B; Yao D
Theranostics; 2023; 13(2):787-809. PubMed ID: 36632213
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Promoting ATAD2 and Its Preclinical Challenges.
Liu H; Wen Q; Yan S; Zeng W; Zou Y; Liu Q; Zhang G; Zou J; Zou X
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008934
[No Abstract] [Full Text] [Related]
11. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based design, synthesis and biological evaluation of theophylline derivatives as ATAD2 inhibitors in BT-549 cells.
Yao D; You J; Yang X; Zhang J; Yao X
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2242601. PubMed ID: 37533352
[TBL] [Abstract][Full Text] [Related]
13. Malignant genome reprogramming by ATAD2.
Boussouar F; Jamshidikia M; Morozumi Y; Rousseaux S; Khochbin S
Biochim Biophys Acta; 2013 Oct; 1829(10):1010-4. PubMed ID: 23831842
[TBL] [Abstract][Full Text] [Related]
14. Structure of the human ATAD2 AAA+ histone chaperone reveals mechanism of regulation and inter-subunit communication.
Cho C; Ganser C; Uchihashi T; Kato K; Song JJ
Commun Biol; 2023 Sep; 6(1):993. PubMed ID: 37770645
[TBL] [Abstract][Full Text] [Related]
15. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
16. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication.
Koo SJ; Fernández-Montalván AE; Badock V; Ott CJ; Holton SJ; von Ahsen O; Toedling J; Vittori S; Bradner JE; Gorjánácz M
Oncotarget; 2016 Oct; 7(43):70323-70335. PubMed ID: 27612420
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
18. ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE.
Guruvaiah P; Chava S; Sun CW; Singh N; Penn CA; Gupta R
Cell Death Dis; 2023 Jul; 14(7):456. PubMed ID: 37479754
[TBL] [Abstract][Full Text] [Related]
19. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.
Poncet-Montange G; Zhan Y; Bardenhagen JP; Petrocchi A; Leo E; Shi X; Lee GR; Leonard PG; Geck Do MK; Cardozo MG; Andersen JN; Palmer WS; Jones P; Ladbury JE
Biochem J; 2015 Mar; 466(2):337-46. PubMed ID: 25486442
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based screening of the bromodomain of ATAD2.
Harner MJ; Chauder BA; Phan J; Fesik SW
J Med Chem; 2014 Nov; 57(22):9687-92. PubMed ID: 25314628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
